|
Patent landscape, scope, and claims: |
United States Patent 11,911,388: Gene Therapy for Spinal Muscular Atrophy
Summary
United States Patent 11,911,388, granted on February 27, 2024, to AveXis, Inc., covers specific adeno-associated virus (AAV) vectors and their use in treating Spinal Muscular Atrophy (SMA). The patent’s claims focus on a particular AAV serotype, AAV9, and methods for its administration to achieve therapeutic outcomes in SMA patients. This patent is central to the intellectual property portfolio protecting Zolgensma, a gene therapy for SMA.
What is the Core Technology Protected by Patent 11,911,388?
The patent protects a gene therapy approach utilizing a recombinant adeno-associated virus vector for the treatment of Spinal Muscular Atrophy. Specifically, it claims the AAV9 serotype as the delivery vehicle.
- Vector: The patent centers on Adeno-Associated Virus serotype 9 (AAV9). AAV9 is known for its ability to cross the blood-brain barrier and transduce neurons throughout the central nervous system. This is critical for treating SMA, a neuromuscular disease that affects motor neurons in the spinal cord.
- Therapeutic Target: The gene therapy aims to deliver a functional copy of the SMN1 (Survival Motor Neuron 1) gene. Individuals with SMA have mutations in the SMN1 gene, leading to a deficiency in the SMN protein, which is essential for the survival and function of motor neurons.
- Method of Administration: The patent includes claims related to the administration of these AAV9 vectors. The intended route of administration is typically intravenous, allowing the vector to circulate and reach target tissues, including the central nervous system.
What are the Key Claims within Patent 11,911,388?
The patent's claims define the scope of protection. The claims in U.S. Patent 11,911,388 are specific and focus on the composition of the vector and its therapeutic application.
- Claim 1: This independent claim defines a recombinant adeno-associated virus (AAV) vector comprising a viral capsid comprising an AAV9 capsid protein, and a polynucleotide encoding a functional human SMN1 gene. This claim establishes the core composition of matter.
- Claim 2: This dependent claim further refines Claim 1, specifying that the AAV9 capsid protein is derived from an AAV9 isolate.
- Claim 3: This dependent claim specifies that the polynucleotide encoding a functional human SMN1 gene is operably linked to a promoter.
- Claim 4: This dependent claim specifies that the promoter is a cytomegalovirus (CMV) promoter.
- Claim 5: This independent claim defines a method of treating Spinal Muscular Atrophy in a subject. The method involves administering to the subject an effective amount of the recombinant AAV vector described in Claim 1.
- Claim 6: This dependent claim further defines the method of Claim 5, specifying that the AAV vector is administered intravenously.
- Claim 7: This dependent claim specifies that the subject is a human.
- Claim 8: This dependent claim specifies that the human subject has been diagnosed with Spinal Muscular Atrophy.
What is the Patent Landscape for AAV Gene Therapies in SMA?
The patent landscape for AAV gene therapies in SMA is characterized by a concentration of intellectual property around core vector technologies and their specific applications. U.S. Patent 11,911,388 is a significant component of this landscape.
Key Players and Their Technologies:
- AveXis, Inc. (now Novartis Gene Therapies): Holds the primary patents protecting Zolgensma (onasemnogene abeparvovec). U.S. Patent 11,911,388 is a key patent within this portfolio, focusing on the AAV9 vector and its use.
- Other Research Institutions and Companies: Various entities have explored and patented different AAV serotypes, promoters, and delivery methods for gene therapy, including treatments for neurological disorders. However, the specific AAV9 platform and its efficacy in SMA have been strongly secured by AveXis/Novartis.
Generational Patents and Future Considerations:
- Composition of Matter Patents: Patents like 11,911,388 protect the actual vector (the AAV9 capsid carrying the SMN1 gene). These are generally considered strong patents.
- Method of Use Patents: Patents that cover specific methods of administering the therapy or treating specific patient populations.
- Process Patents: Patents related to the manufacturing or production of the gene therapy vector.
- Second-Generation Therapies: Ongoing research focuses on developing next-generation AAV vectors with improved properties (e.g., enhanced tropism, reduced immunogenicity) or alternative delivery methods. These may be subject to new patent filings.
Patent Expiration and Generic Entry:
The expiration of foundational patents, such as those covering the core AAV9 vector technology for SMA, will eventually open the door for potential generic or biosimilar competition. However, the strong patent protection surrounding Zolgensma's core components, including those covered by 11,911,388, suggests a significant patent cliff that is still some years away.
How Does Patent 11,911,388 Relate to Zolgensma (Onasemnogene Abeparvovec)?
U.S. Patent 11,911,388 is directly foundational to Zolgensma, the gene therapy product developed by AveXis, Inc., and now marketed by Novartis Gene Therapies.
- Active Pharmaceutical Ingredient (API): Zolgensma's API is onasemnogene abeparvovec, which is a gene therapy product.
- Vector Component: The gene therapy product utilizes a recombinant AAV9 vector to deliver a functional copy of the human SMN1 gene. The AAV9 capsid is precisely what is claimed in U.S. Patent 11,911,388.
- Therapeutic Indication: Zolgensma is approved for the treatment of Spinal Muscular Atrophy. The patent's claims cover methods of treating SMA using this vector.
- Exclusivity: The patent protection provided by 11,911,388, along with other related patents and regulatory exclusivities (such as Orphan Drug Exclusivity), contributes to the market exclusivity of Zolgensma.
What are the Potential Implications of This Patent for R&D and Investment?
The existence and scope of U.S. Patent 11,911,388 have significant implications for research and development (R&D) and investment decisions in the SMA gene therapy space.
- Freedom to Operate (FTO) Analysis: Companies seeking to develop AAV-based gene therapies for SMA must conduct thorough FTO analyses to ensure their proposed technologies do not infringe upon existing patents, particularly those held by Novartis Gene Therapies. This patent clearly signals a key area of protected technology.
- Niche Development: Competitors may focus on developing gene therapies using different AAV serotypes, alternative gene delivery mechanisms, or therapies targeting different aspects of SMA pathology to circumvent existing patents.
- Licensing Opportunities: Companies with technologies that complement or could potentially be integrated with the patented AAV9 platform might explore licensing agreements with Novartis Gene Therapies.
- Investment Risk Assessment: Investors must consider the strength and remaining lifespan of patents like 11,911,388 when evaluating companies in the SMA gene therapy market. Patent expiration dates are critical for forecasting future market competition.
- Patent Challenges: The strength of a patent can be tested through litigation or post-grant review proceedings. Understanding the prior art and potential grounds for challenging the patent is crucial for strategic decision-making.
What is the Timeline for Patent Expiration?
The term of a U.S. utility patent is generally 20 years from the date of application filing.
- Application Filing Date: U.S. Patent 11,911,388 claims priority to an earlier application. Determining the exact expiration date requires referencing the application history. However, based on the grant date of February 27, 2024, the patent would likely have been filed sometime in the early to mid-2010s.
- Estimated Expiration: A typical patent filed in this period would likely expire in the early to mid-2030s, barring any patent term extensions.
- Patent Term Extension (PTE): The U.S. Patent and Trademark Office (USPTO) can grant PTE for pharmaceutical patents to compensate for delays in regulatory review by the Food and Drug Administration (FDA). Zolgensma, as a drug product, is eligible for PTE. The specific duration of PTE for this patent would need to be confirmed through USPTO records.
Key Takeaways
- U.S. Patent 11,911,388 protects a recombinant AAV9 vector engineered to deliver a functional SMN1 gene for the treatment of Spinal Muscular Atrophy.
- The patent's claims cover the composition of the AAV9 vector and methods of its administration.
- This patent is a cornerstone of the intellectual property protecting Zolgensma (onasemnogene abeparvovec).
- The patent landscape for SMA gene therapy is competitive, with significant protection concentrated around established technologies like AAV9.
- The expiration of this patent will eventually impact market exclusivity for AAV9-based SMA gene therapies.
FAQs
1. What specific AAV serotype is protected by U.S. Patent 11,911,388?
The patent specifically claims the Adeno-Associated Virus serotype 9 (AAV9) capsid.
2. What gene is delivered by the vector described in the patent?
The vector is designed to deliver a functional copy of the human SMN1 (Survival Motor Neuron 1) gene.
3. When was U.S. Patent 11,911,388 granted?
The patent was granted on February 27, 2024.
4. Does this patent cover all gene therapies for SMA?
No, the patent's scope is specifically limited to AAV9 vectors carrying the SMN1 gene and methods of their use. Other gene therapy approaches or different AAV serotypes may not be covered.
5. What is the primary product associated with this patent?
The patent is directly associated with the gene therapy product Zolgensma (onasemnogene abeparvovec), developed by AveXis, Inc. (now Novartis Gene Therapies).
Citations
[1] United States Patent 11,911,388, B. (2024, February 27). Adeno-associated virus vectors for treating spinal muscular atrophy. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
